Article ID Journal Published Year Pages File Type
5592684 Cardiovascular Revascularization Medicine 2017 25 Pages PDF
Abstract
In severe AS patients with non-high surgical risk, TAVR has lower risk of MI at one month, but both TAVR and SAVR yielded similar outcomes at one month in terms of mortality and CVA and at 12 months in terms of mortality, CVA and MI. In regard to secondary outcomes at one month, TAVR has lower rates of bleeding and acute kidney injury, and higher rates of need for new permanent pacemakers and high rate of vascular access site complications.
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Molecular Medicine
Authors
, , , , , ,